INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
447.45 EUR
-4.35 (-0.96%)
IUI1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 67 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IUI1 a very profitable company, without any liquidiy or solvency issues. IUI1 shows excellent growth, but is valued quite expensive already. With these ratings, IUI1 could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year IUI1 was profitable.
- In the past year IUI1 had a positive cash flow from operations.
- In the past 5 years IUI1 has always been profitable.
- IUI1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- IUI1's Return On Assets of 14.19% is amongst the best of the industry. IUI1 outperforms 94.03% of its industry peers.
- IUI1 has a better Return On Equity (16.12%) than 83.58% of its industry peers.
- IUI1 has a better Return On Invested Capital (11.69%) than 82.09% of its industry peers.
- IUI1 had an Average Return On Invested Capital over the past 3 years of 9.53%. This is in line with the industry average of 9.84%.
- The last Return On Invested Capital (11.69%) for IUI1 is above the 3 year average (9.53%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
- With an excellent Profit Margin value of 28.58%, IUI1 belongs to the best of the industry, outperforming 98.51% of the companies in the same industry.
- IUI1's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 29.44%, IUI1 belongs to the top of the industry, outperforming 98.51% of the companies in the same industry.
- In the last couple of years the Operating Margin of IUI1 has declined.
- IUI1's Gross Margin of 66.38% is fine compared to the rest of the industry. IUI1 outperforms 73.13% of its industry peers.
- IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
- Compared to 1 year ago, IUI1 has more shares outstanding
- Compared to 5 years ago, IUI1 has more shares outstanding
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.16
WACC10.05%
2.3 Liquidity
- IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
- IUI1's Current ratio of 4.97 is amongst the best of the industry. IUI1 outperforms 95.52% of its industry peers.
- A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
- IUI1's Quick ratio of 4.20 is amongst the best of the industry. IUI1 outperforms 95.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 28.12% over the past year.
- Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
- Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
- Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 13.27% on average per year.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
- Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.67% on average per year.
- IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.12% yearly.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue Next Year21.33%
Revenue Next 2Y18.13%
Revenue Next 3Y16.56%
Revenue Next 5Y14.12%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 61.04, the valuation of IUI1 can be described as expensive.
- IUI1's Price/Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 61.19% of the companies in the same industry.
- When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (27.32), we can say IUI1 is valued expensively.
- Based on the Price/Forward Earnings ratio of 52.93, the valuation of IUI1 can be described as expensive.
- 73.13% of the companies in the same industry are cheaper than IUI1, based on the Price/Forward Earnings ratio.
- IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.04 | ||
| Fwd PE | 52.93 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 67.16% of the companies listed in the same industry.
- The rest of the industry has a similar Price/Free Cash Flow ratio as IUI1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 81.98 | ||
| EV/EBITDA | 51.54 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.90% in the coming years.
PEG (NY)3.03
PEG (5Y)5.32
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
- IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (1/21/2026, 7:00:00 PM)
447.45
-4.35 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-21 2025-10-21/amc
Earnings (Next)01-22 2026-01-22/amc
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap158.62B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts77
Price Target531.45 (18.77%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)1.34%
PT rev (3m)3.73%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)1.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.04 | ||
| Fwd PE | 52.93 | ||
| P/S | 19.37 | ||
| P/FCF | 81.98 | ||
| P/OCF | 62.89 | ||
| P/B | 10.93 | ||
| P/tB | 11.15 | ||
| EV/EBITDA | 51.54 |
EPS(TTM)7.33
EY1.64%
EPS(NY)8.45
Fwd EY1.89%
FCF(TTM)5.46
FCFY1.22%
OCF(TTM)7.11
OCFY1.59%
SpS23.1
BVpS40.95
TBVpS40.12
PEG (NY)3.03
PEG (5Y)5.32
Graham Number82.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC10.05%
ROIC/WACC1.16
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.33%
Revenue Next 2Y18.13%
Revenue Next 3Y16.56%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.85%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.